Hikma US unit launches anti-HIV tablet

Generic drug maker Hikma Pharmaceuticals said its US subsidiary West-Ward had launched Ritonavir Tablets, the first AB-rated generic to Norvir tablets.

Citing an approval letter from the US Food and Drug Administration, Hikma said West-Ward was eligible for 180 days of generic drug exclusivity.

West-Ward's ritonavir is approved by FDA for use in combination with other antiretroviral agents for treatment of human immunodeficiency virus (HIV-1) infection.

West-Ward generics division president Brian Hoffmann said the company would be launching ritonavir with additional patient support and co-pay assistance “to ensure more people are able to access this life-saving medicine".

He added that West-Ward was launching an education and awareness campaign, including a website and direct communication.

According to medical information company IQVIA, US sales of Norvir were approximately $208.5m in 2017.